Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Equity (Details Narrative)

Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended	3 Months Ended				6 Months Ended
	Jan. 15, 2020	Jan. 10, 2020	Jan. 31, 2020	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Sep. 20, 2019
Preferred stock aggregate value					$ 1	$ 73	$ 1
Preferred stock dividend percentage								6.00%
Stock issued								178,000
Sale of net proceeds								$ 700
Series B Preferred Stock [Member]
Preferred stock adjusted conversion	$ 6.00
Company achieve revenue target			$ 34,000
Intrinsic value of beneficial conversion feature	$ 2,200
Intrinsic value of effective conversion price per share	$ 6.79
Series B [Member]
Aggregate of shares issued								27,000
Preferred stock adjusted conversion								$ 6.00
Series A [Member]
Preferred stock par/stated value				$ 0.01				$ 0.01
Aggregate of shares issued								270
Value of preferred stock exchanged								$ 27,000
Preferred shares stated value				$ 100,000				$ 100,000
Preferred stock adjusted conversion								$ 8.00
Security Purchase and Exchange Agreement [Member] \| Series B Convertible Preferred Stock [Member]
Preferred stock aggregate value		$ 20,000
Security Purchase and Exchange Agreement [Member] \| Series B [Member]
Preferred stock par/stated value		$ 0.01
Issuance price of preferred stock		$ 1,000
Security Purchase and Exchange Agreement [Member] \| Series B [Member] \| 1315 Capital [Member]
Preferred stock aggregate value		$ 19,000
Aggregate of shares issued		19,000
Security Purchase and Exchange Agreement [Member] \| Series B [Member] \| Ampersand 2018 Limited Partnership [Member]
Preferred stock aggregate value		$ 1,000
Aggregate of shares issued		1,000
Equity Distribution Agreement [Member]
Aggregate offering price									$ 4,800
Fixed percentage of commission									3.00%